Ann Merrifield

Ms. Merrifield serves as InVivo’s Chair of the Board. She also holds positions both as Chair of the Nominating and Corporate Governance Committee and a member of the Compensation Committee. She currently serves as a board director for a number of public companies which include Flexion Therapeutics, Lyra Therapeutics, and MassMutual Premier, MML, Select, and MMLII Funds, a portfolio of mutual funds. She also previously served on the board of Juniper Pharmaceuticals until it was acquired by Catalent, and also previously served on the board of Veritas Genetics. Most recently, Ms. Merrifield was President and Chief Executive Officer at PathoGenetix, a genomics company that developed and commercialized an automated system for rapid bacterial identification from complex samples. Before joining PathoGenetix, Ms. Merrifield served in a number of leadership roles at Genzyme Corporation. In her most recent position, she was selected by the CEO to serve as Senior Vice President, Business Excellence, before the Sanofi acquisition. Prior to that, she served as President of Genzyme Biosurgery, where she led a turnaround from an over $75M loss to a profit of more than $200M. She served as President of Genzyme Genetics before her position at Genzyme Biosurgery, where she shaped the company’s genetic diagnostics business through product and service differentiation and strategic acquisitions. Ms. Merrifield came to Genzyme from Bain and Company, where she was a partner, and Aetna Life & Casualty, where her role was as an investment officer. Ms. Merrifield earned a B.A. in zoology and an M.A. in education from the University of Maine, and an MBA from the Amos Tuck School of Business at Dartmouth College.